Deposition of amyloid β (Aβ) fibers in extra-cellular matrix of the brain is a ubiquitous feature associated with several neurodegenerative disorders, especially Alzheimer's disease (AD). While many of the biological aspects that contribute to the formation of Aβ plaques are well addressed at the intra-and inter-cellular level in short timescales, an understanding of how Aβ fibrillization usually starts to dominate at a longer timescale in spite of the presence of mechanisms dedicated to Aβ clearance, is still lacking. Furthermore, no existing mathematical model integrates the impact of diurnal neural activity as emanated from circadian regulation to predict disease progression due to a disruption in sleep-wake cycle. In this study, we develop a minimal model of Aβ fibrillization to investigate the onset of AD over a long time-scale. Our results suggest that the diseased state is a manifestation of a phase change of the system from soluble Aβ (sAβ) to fibrillar Aβ (fAβ) domination upon surpassing a threshold in the production rate of soluble Aβ. By incorporating the circadian rhythm into our model, we reveal that fAβ accumulation is crucially dependent on the regulation of sleep-wake cycle, thereby indicating the importance of a good sleep hygiene in averting AD onset. We also discuss potential intervention schemes to reduce fAβ accumulation in the brain by modification of the critical sAβ production rate.
Introduction
Amyloid β (Aβ) accumulation is a common pathological characteristic of several neurodegenerative and neuroinflammatory disorders, essentially Alzheimer's disease (AD) [1, 2] . The clinical symptoms and cellular dysfunction that contribute towards pathological burden in AD are generally considered to be the outcome of neurodegenerative effects of the formation of Aβ plaques in the extra-cellular space [3] and neurofibrillary tangles of τ protein in neurons [4] . Regulation of Aβ levels in the interstitial fluid (ISF) is mediated by circadian rhythm [5] , which also modulates the neuro-immuneendocrine system through several complex biochemical mechanisms [6, 7, 8] . Thus, it might be possible that the circadian rhythm and the emergence of neurodegenerative disorders have a bidirectional modulatory relationship with each other. For example, the sleep-wake cycle is known to be altered several years before the onset of AD [9, 10] , and prolonged neuroinflammation may also contribute to worsen the sleep hygiene.
It is often debated whether alteration in the sleep rhythm is a causal player in AD, or it only correlates with it [11, 9, 10] . There exists a positive correlation between the circadian gene expression and the number of hypothalamic neurons in the suprachiasmatic nucleus (SCN) that acts as a master regulator of circadian rhythm [12, 13] . An intriguing fact in this regard is that a significant loss of neurons is found in the SCN of the mammals debilitated with AD [14] , which may suggest why the sleepwake cycle is disrupted in a broad range of neuroinflammatory disorders. Moreover, a disturbance in the sleep hygiene is found to correlate with Aβ deposition in the brain [15] .
Aβ is produced by neurons upon synaptic activity and released into the ISF [16, 17] , thereby having an interplay with neural activity. As the SCN controls diurnal neural activity through circadian rhythm, the secretion of Aβ into the ISF follows a similar diurnal rhythm in normal circumstances. This implies that a disturbance in the sleep-wake cycle or unchecked deprivation in sleep may result in higher Aβ production through higher neural activity and may also lead to Aβ neurotoxicity and oxidative stress to neurons. As a consequence, a disrupted central circadian rhythm results in altered hippocampal Aβ rhythm and causes accumulation of amyloid plaques.
Aβ plaques that contribute to neurotoxicity disturb the neural function in the SCN and impair the regulation of circadian neural activity throughout the brain [12] . This acts as a positive-feedback loop resulting in more Aβ accumulation in the SCN, more neurotoxicity to the SCN, less regulation of the global brain diurnal rhythm, and Aβ secretion as well as subsequent fibrillization.
As there are a plethora of factors that can contribute to neuroinflammation and neurodegeneration as we age, it is practically impossible to take all the details in shorter timescales (e.g. milliseconds in case of neuronal firing rate), and draw a broad unified picture of the disease development over an extremely long timescale, i.e., in years. Thus, it will be intriguing to design a mean-field approach where one can, starting from the key components of the underlying system, understand the transition into the diseased state characterized by Aβ fibrillization long before the patho-physiological symptoms occur and neuroinflammatory response starts. We propose a minimal model and show that the onset of AD is driven by a phase change from the soluble form of Aβ to its fibrillar form. The proposed model has the advantage of simplicity compared with the recent mathematical models [18, 19, 20, 21] . A few other in-silico studies explained how the Aβ fibres form in the brain, using an agent-based model [22] or numerically solving the partial differential equations [21, 23] . Although many aspects of the disease are explained and understood from these models, we still lack a simple explanation of how different factors affect the brain in the course of AD.
In this paper, we employ a minimal mathematical model based on ordinary differential equations (ODEs) to investigate Aβ fibrillization in the brain, and its dependence on associated factors such as Aβ production by neurons and their clearance by microglia or efflux through the cerebrospinal fluid (CSF). Our results suggest that the accumulation of fibrillar Aβ can be viewed as a shift in the scaling law between the concentration of fibrillar Aβ and soluble Aβ production rate due to neuronal activity. Our work also predicts that even a two-fold increase in Aβ production may trigger a phase change from soluble Aβ to fibrillar Aβ. The current ODE-based model suggests that AD can be seen as the outcome of perturbations in brain homeostasis. We believe that such a minimal model could also pave a way for new potential treatments or prevention strategies.
Methods
We base the mathematical model on major mechanisms regulating the fibrillization process, namely fibrillar Aβ formation from soluble Aβ, Aβ production by neurons, and their clearance by glial cells or efflux through the CSF.
The interaction network of the fibrillization of Aβ in AD is depicted in Fig. 1 . The changes in the number and activity of astrocytes, neurons, and microglia are ignored. The cycling time of microglia is much faster (a few days) than the time scale of Aβ accumulation (a few years). Thus, we assume that the number of activated microglia reaches its carrying capacity through a fast logistic growth due to proliferation in the presence of sAβ and fAβ. We assume that the number of neurons do not vary significantly over the course of the onset of Aβ fibrillization [38, 39] such that the production rate of Aβ, R, remains stable for a long period of time. With the aforementioned biological assumptions, the equation for the rates of change in Aβ concentrations in the ODE-based model, depicted in Fig. 1 , can be obtained as 
where S and F are the concentration of Aβ oligomers in soluble (S ≡ [sAβ]) and fibrillar form (
resents the number density of microglia. Over-dots denote time derivative (Ẋ ≡ dX/dt). R is the rate of sAβ production over a day due to neural synaptic activity. Although the production rate has a circadian pattern, its day average is used as an approximation. k n and k p are the Aβ nucleation and polymerization rates, respectively.
The parameter values are provided in Tab. 1.
The biological observations and associated modeling assumptions are explained as follows.
sAβ efflux It has been found that meningeal lymphatics plays an important role in the clearance of the brain waste including sAβ [40, 41, 42] . The efflux of sAβ to the meningeal lymphatics and CSF is independent of the existence of microglia and is driven by diffusion. The efflux rate of sAβ in the CSF, e s , has been [36] * Estimation of k n and k p has been done using the differential evolution method [37] (see Fig. S1 ).
reported to be around 7.6 to 8.3 % per hour [34, 35] (i.e. e s = 1.9 ± 0.4 day −1 ).
Aβ clearance by microglia Fibrillar Aβ (fAβ) is cleared by microglia through phagocytosis while its soluble form (sAβ) is cleared through macropinocytosis [43, 31] , a process mediated by cellular internalization. Macropinocytosis is linearly dependent on the concentration of the entities that are internalized by the cell. Thus, the rate of sAβ clearance does not saturate because of such a mechanism. In contrast, fAβ ligates a receptor on microglia and its phagocytosis is better represented by a saturable rate obeying the Michaelis-Menten kinetics [44] . Nevertheless, the clearance or decay rates of sAβ and fAβ are modeled similarly, assuming that the number of microglia receptors is much greater than the number of Aβ, while keeping in mind that such an assumption is not valid at high concentrations of fAβ. However, it applies well to the early stage of the disease. The concentration of sAβ, S ≡ [sAβ] and fAβ, F ≡ [fAβ] decrease in time by the rates d s M and d f M .
It was observed that the intracellular concentration of sAβ depends linearly on the concentration of sAβ in the tissue (as a result of macropinocytosis) [31] . Furthermore, the intracellular concentration of sAβ decays exponentially. With this, the clearance rate of sAβ by microglia is estimated as 0.22 h −1 N mgl V mgl /V brain , assuming a 100% uptake by microglia, with N mgl , V mgl and V brain being the total number of microglial cells, the volume of microglial cell and the total volume of the brain, respectively. Microglia have a plethora of shapes and sizes according to their activation states [32, 33] making the estimation for V mgl challenging. Here, it is assumed that V mgl is in the order of 1000 µm 3 , leading to d s = 0.22 × 10 −9 h −1 mL. It is roughly estimated that d f is 30 times smaller than d s [36] . With the estimated values, microglial clearance composes 20% of the whole clearance, while the efflux has a greater share of 80%.
Fibrillization process Shortly after the introduction of amyloid cascade hypothesis [45] , the fibrillization of Aβ has been investigated extensively by many scientists [46] . According to the seminal model for amyloid fibrillization proposed by Lomakin et al. in 1997 [47] , the accumulation of Aβ is driven through two distinct pathways, the initial nucleation and the secondary nucleation by adjoining of soluble Aβ to amyloid fibers [47] . Although the amyloid aggregation is still an active field of research, there is a consensus that such a phenomenon occurs through these two mechanisms. The secondary nucleation has been understood as the leading mechanism for amyloid plaque formation in AD [48, 49, 50] .
We take the most simple form of amyloid aggregation, considering a primary and secondary nucleation, referred to as nucleation and polymerization, respectively. In the primary nucleation, soluble Aβ come together and form small fibers with the nucleation rate k n . In the secondary nucleation, soluble Aβ adjoin the fibers with polymerization rate k p . The required energy for Aβ nucleation is one order of magnitude higher than for their polymerization [51] , implying that the polymerization rate is much greater than the nucleation rate (k p k n ). In order to calibrate the model parameters with the experimental results, the recent ThT experiments of amyloid aggregations [30] , upon which many kinetic models of polymer aggregation are being validated [52, 53, 54] have been used. The estimated values for k n and k p are tabulated in Tab. 1 (see also Fig. S1 ).
The large difference between the values of k p and k n , and the scaling of Aβ nucleation with S 2 due to their selfinteraction are essential in determining an abrupt phase change from soluble to fibrillar Aβ. Such a fibrillization dynamics is in qualitative agreement with the complex kinetic models for amyloid fibrillization [55, 54, 53, 56, 47] .
Results and Discussion
The emergence of a soluble and a fibrillar phase with distinct scaling laws.
We assume that a healthy brain in its initial state does not have any fAβ and is characterized by sAβ production due to neuronal activity. Formation of sAβ by neurons sets Aβ dynamics in the system and initiates the interplay between several biological processes as discussed above. As the "diseased" state of the brain in AD is marked by a high concentration of fAβ, it becomes primarily important to understand how the dynamics of the system may result in fAβ formation in the extracellular matrix and how it would depend on the production rate of sAβ, R. To perceive this, we first calculate the steady state of our model system and depict its dependence on R (Fig. 2) . Considering that the system starts with zero concentration of fAβ, the steady-state
and
where α = R/λ s , β = λ f /λ s , γ = k p /k n , δ = λ s /k n , and ∆ = (αγ/β) 2 + δ 2 + 4αδ − 2δαγ/β. We note that Eq. (4) has only one positive solution for the biologically plausible parameter values listed in Tab. 1. The steady-state solutions of the system variables, F ∞ and S ∞ , are depicted in Fig. 2 . We observe that there is a critical Aβ production rate (R c ) at which the scaling relation of these steady-state solutions with respect to R changes (see Fig. 2 -A for F ∞ and Fig. 2 -B for S ∞ ). Mathematically, R c is the point where ∆ takes its minimum value with respect to α (R c = λ s δβ(γ − 2β)/γ 2 ). Below R c , F ∞ scales as the second power of R, reflecting that nucleation is the leading mechanism of fibrillization. Above R c , the scaling of F ∞ changes to the first power of R, implying that polymerization (i.e. adjoining of single oligomers to amyloid fibers) is the leading mechanism. S ∞ scales with respect to R with an exponent of unity below R c and zero above it. It means that the system of ODEs predicts a saturation point for sAβ. The system has two distinct phases, a phase dominated by soluble Aβ, and another dominated by Aβ in fiber form. As depicted in Fig. 2 -A, the fAβ concentration between the two phases differs by many orders of magnitude, which suggests a clear distinction of the "diseased" state as compared to the "healthy" one.
The time that the system variable F takes to reach 99% of its steady-state value is defined as the settling time τ 0.99 , as depicted in the inset diagram of Fig. 2 
The settling time is a measure of how fast the system reaches its steady-state. We note that the shortest settling time is around one year while it exceeds 100 years as the system moves toward the critical value of the Aβ production rate R c (see Fig. 2-C) . As can be seen from Fig. 2 -C, τ 0.99 varies sharply at the close proximity to R c , whereas it retains lower values in either side of R c and away from it.
We next estimate the biologically plausible range of R in the case of humans. It has been shown that Aβ levels in the human brain fluctuate with a diurnal rhythm, whose mesors are around 2.3 × 10 −4 µM for Aβ42 and 2.6 × 10 −3 µM for Aβ40, with normalized amplitudes of 10 to 20% [24] . The production rate of sAβ has been reported to be around 6-8% per hour in the CSF [34, 35] , implying the physiological plausible range of R ≈ 3 × 10 −4 -5 × 10 −3 µM/day (shown by the red-highlighted vertical band in Fig. 2 ). Please note that R c belongs to this range based on the values tabulated in Tab. 1.
Transformation into fibrillar phase depends critically on the system parameters.
As the alteration of the phase of Aβ from soluble to fibrillar crucially depends on the critical sAβ production rate R c , it is intriguing to explore the various means to shift the value of R c to unravel the impact of the distinct underlying biological processes that give rise to the fibrillar phase dominated by fAβ. It may also uncover potential medical intervention strategies for the prevention or delay of AD onset. To elucidate this, we have studied how a modification in each of the system parameters, listed in Tab. 1 affects R c . As expected, R c is dependent on the parameters of the model. It scales inversely with k p (Fig. S3 ), and linearly with e s (Fig. S4 ) and d f (Fig. S2) . Here, as an example, we investigate the effect of parameter M in more details. We observe that R c scales superlinearly with M as depicted in the inset of Fig. 3-A . The steady-state solutions of the system variables (F ∞ and S ∞ ) are also shown for several values of M in Fig. 3 . Whereas F ∞ decreases as we increase M (Fig. 3-A) , S ∞ shows a complex trend ( Fig. 3-B ). For a characteristic R which is beyond R c 's for all the microglial densities in consideration, S ∞ attains a larger value for a higher microglial density ( Fig. 3-B ). Furthermore, as can be seen from Fig. 3 -C, the settling time (τ 0.99 ) decreases as R c (or M ) increases. In general, the results suggest that an efficient clearance of sAβ by microglia and an enhanced sAβ efflux through CSF diminish the risk of developing AD, whereas a high rate of Aβ fiber growth or higher rate of sAβ production makes an individual prone to AD.
Time-dependent parametric perturbations can induce accumulation of Aβ fibers: role of clearance processes and astrocytes.
The physiological processes, that have been taken into consideration in the model, might encounter a plethora of biological perturbations which may reflect as alteration in the system parameters in a time-dependent manner. Such systemic perturbations can arise from inflammatory conditions or even from a new sleeping habit. Any of our model parameters can get altered for a certain duration due to such a change in the micro-environment of the brain. As the settling time and the steady-state concentration of fAβ are both dependent on the critical sAβ production rate R c , any time-dependent or persistent perturbation in the system parameters resulting in even a slight change of R c may have a significant impact on the amount of fAβ. Whether the system would evolve to a phase dominated by fAβ and how rapidly the system would recover from the effect of such a transient modification in a system parameter, crucially depend on the change in R c due to the parametric perturbation. If R exceeds the modified R c , the fibrillar phase starts to dominate resulting in a rapid production of fAβ. The recovery time t recov which is defined as the time required for the system variable F to settle to 99% of its original steady state value (before parametric perturbation), may be relatively longer if the system faces a strong or a long perturbation.
To illuminate this, as an example, we have reduced the microglia density, M , to one tenth (1/10) of its original value for several perturbation period t pert and analyzed how the concentration of fAβ evolves as a result of this parametric perturbation both during and after t pert (Fig. 4) . The time of recovery, t recov , lengthens as we increase t pert . Furthermore, we note that the concentration of fAβ at the end of the perturbation period increases considerably with t pert as depicted in the left inset of Fig. 4 . This suggests that the possibility of developing Alzheimer's disease (AD) can be much higher if the microglial density drops abruptly even for a year. Disturbed circadian rhythm can be a key factor in the emergence of AD.
As the production and clearance of Aβ both are regulated by the circadian rhythm, it is crucial to consider the impact of a disrupted sleep-wake cycle on Aβ accumulation.
While the model omits an explicit consideration of circadian rhythm in the production rate, it still allows to gain insight into a more realistic setting which includes a circadian rhythm of Aβ production. Moreover, a jejune idea of taking the average of the sAβ production rate in order to predict the final phase of the system (soluble or fibrillar) does not work in cases where the sAβ production rate oscillates daily around R c due to variations of neural activity in wake and sleep states ( Fig. 5-A) . Under these circumstances, even a small alteration in the sAβ production rate may result in a significant change in the settling time close to R c thereby making the final phase of the system closely dependent on the sleep-wake cycle.
This regulatory aspect is essential as the production rate of sAβ is estimated to lie in a physiological plausible range (the red-highlighted vertical bands in Fig. 2 ) which includes its critical value R c . We assume that the diurnal rhythm of overall neural activity results in a diurnal pattern in the production rate of sAβ, which is represented by a rectangular periodic functionR for mathe-matical simplicity ( Fig. 5-B ).R fluctuates between the wake (w) and sleep (s) courses, each with a specific sAβ production rate R w and R s , and a duration of τ w and τ s , respectively. We define the normalized circadian amplitude as a = (R w − R s )/(R w + R s ). Since both the settling time and the steady-state value of fAβ concentration depend on the production rate sAβ, the mean accumulation of fAβ is determined by a and τ s , especially when the production rate is in a close neighborhood of R c . The daily accumulation of fAβ is estimated as F w ∞ τ w /τ w 0.99 +F s ∞ τ s /τ s 0.99 , and depicted in Fig. 5 -C. The settling time to reach the steady-state value F ∞ , varies widely for differentR around the critical point R c . As can be seen from Fig. 5 -C, accumulation of fAβ per day is significantly reduced by having proper relaxation of the overall neural activity, for instance through sleeping. Although the circadian amplitude a also plays a pivotal role in this regard, τ s outweighs the impact of a as long as a is high enough to put the production rate of sAβ below R c during sleep. Thus, a good sleep hygiene can be an important protective factor to curtail the accumulation of Aβ in its fibrillar form, thereby averting the onset of AD.
Potential intervention strategies to prevent or delay fibrillization by elevating R c
We next consider several potential intervention schemes, reducing fAβ accumulation in the brain to prevent/treat AD by elevating the critical sAβ production rate R c . In a neuro-pathological milieu, different drugs may affect different parameters of the model. An impact of a drug on the parameter x can be modeled as either (1 − ε x )x for a drug that decreases the value of a parameter (inhibitory drug), where ε x ∈ [0, 1] or (1 + ε x )x for a drug that enhances the value of a parameter (stimulatory drug), where ε x ≥ 0, ε x being the efficacy of the drug on parameter x. Hence, in order to lift R c , the potential strategies should have an inhibitory effect for the parameters R and k p (e.g. R → (1 − ε R )R), while the rest of the system parameters are to be under a stimulatory treatment (e.g.
First, we consider a "monotherapy" that alters only one parameter in the system. Defining R cn as the nominal value of R c without treatment, Fig. 6 -A shows the variation of R c /R cn for several treatment methods corresponding to the efficacy parameters in the range ε x ∈ [0, 1]. As can be seen from Fig. 6 -A, a reduction in R or k p has the strongest impact on R c because R c ≈ R cn (1 − ε x ) −1 for both x = R and x = k p .
The simultaneous incorporation of two or more such schemes in a "combination therapy" may significantly enhance R c . We note that the impact emanated from inhibition of R and that of k p on R c are too strong to be achieved with the "combination therapy" with any two of the other parameters. Fig. 6-B and -C show changes of R c due to stimulatory effect on the parameter pairs d f -M , and d f -e s , respectively. As expected, the "combi- nation therapy" averts AD by increasing R c remarkably in a nonlinear manner. For instance, where a stimulatory "monotherapy" either on M or d f with ε x = 1 hardly increases R c by 2-fold, a combination of both of these results in around 4.5-fold enhancement of R c (see Fig. 6-B ) pointing towards the efficacy of such an approach. Moreover, a "combination therapy" on two parameters which do not play a significant role apiece, may have higher impact than a "monotherapy" on a more influential parameter. For example, a combination of stimulatory therapy on d f and e s compensates their individual lower impact on increasing R c as compared to the "monotherapy" on M (compare Fig. 6 -C and -A). Our simple model, thus, offers key insight into several options to prevent and treat neuro-inflammatory conditions in the context of fAβ accumulation in the brain.
Conclusion
We have developed a minimal ODE-based model of amyloid β (Aβ) fibrillization in order to understand the initiation of Alzheimer's disease (AD), based on the amyloid cascade hypothesis [45, 2, 57] . Our theoretical framework is based on the balance between Aβ production by neurons and their clearance by microglia or physical discharge through the cerebrospinal fluid (CSF). The model suggests that an imbalance between the production and clearance of Aβ may lead to the formation of fibrillar amyloid plaques (fAβ) which sediment in the brain. Once formed, fAβ are not only more persistent against clearance by microglia, but also trigger the close-by soluble Aβ oligomers (sAβ) for a fast fibrillization. Therefore, the homeostatic state of the brain shifts toward the dominance of fAβ over sAβ, a process associated with the development of Alzheimer's disease (AD) in a long run.
Our model predicts two distinct phases for the system, one dominated by sAβ oligomers and the other dominated by fAβ plaques. It is argued that if the system finds itself in the latter phase, the amyloid plaques gradually form leading to the onset of AD. The two phases are separated by a critical Aβ production rate, R c . The phase change occurs when the production rate R is greater than R c . If the physiological value of R is very close to R c , a perturbation in the production or the clearance of Aβ may trigger the phase change in the system and initiate fibrillization. A retrieve from the fibrillar phase might take years according to our results, implying that the system may not be able to find back its original "healthy" homeostatic state.
The production of Aβ is related to the synaptic activity of neurons [16, 17] . We have studied how the lack in relaxation of the neural activity facilitates the onset of Aβ fibrillization. Various physiological conditions, such as neuroinflammation, trauma, or even disturbances in sleep may affect the neural activity and indirectly lead to the accummulation of Aβ [10] . For instance, a flu infection has been recently shown to have an influence on the activation of microglia and neural impairment on mice long after disease recovery [58] , indicating that an acute infection may lead to a long-term neuroinflammation which in turn changes the brain homeostatic state and neural activity. Our results suggest that short-term perturbations in the system parameters may result in an abrupt increase in Aβ levels which can persist for years after perturbation. Specifically, we used our model to reveal how sleep might play a key role in preventing the development of AD, by reducing the production of Aβ oligomers. These results are in accordance with the observation that AD patients had sleep disturbance problems years before they show symptoms of AD [9, 10] .
Since a reduction of R c could initiate progressive fibrillization of Aβ, the onset of AD could be hindered by the treatment strategies that increase the value of R c . Such an analysis guides us toward new therapeutic or Figure 6 : Intervention strategies. The critical production rate Rc, normalized to its nominal value Rcn, as a function of drug efficacies. The treatment strategy is increasing the value of Rc as much as it exceeds the actual production rate R. This happens when a drug decreases the parameters R or kp, or increases any other parameter. εx is the efficacy of a drug, applying to parameter x. (A) Rc/Rcn for single therapies. (B) and (C) Rc/Rcn for two different combination therapies. prevention strategies. Efflux of sAβ through CSF and the clearance by microglia and astrocytes are the primary ways by which the system can get rid of Aβ. Both of these ways could be modulated by drugs, diseases, and injuries. For example, the efficiency of microglia in fAβ clearance through phagocytosis may be regulated by drugs [59] . These effects could be translated into higher fAβ decay rate. However, one treatment strategy could be more effective than another if the system has a stronger response to it, which is described by the scaling of R c with respect to different parameters. The model shows that R c scales superlinearly with the number of microglia, linearly with their efficiency in clearing Aβ for either the soluble or fibrillar form, and linearly with the efflux rate of sAβ in CSF. It implies that triggering microglial proliferation is more effective in increasing R c than stimulating their efficiency in phagocytosis. According to the model, the direct regulation of sAβ production or polymerization rate of fAβ would be very effective in the prevention of fibrillization and AD onset. First, the impact of Apolipoprotein E4 allele (ApoE4) on the disease progression is as important as the production rate of Aβ because ApoE4 directly affects the polymerization rate [60, 61, 62] . It implies that blocking ApoE4 protein should be one of the most influential intervention strategies for the individuals which carry it. Second, since further reduction of the polymerization rate may require the recruitment of astrocytes or changing the chemical properties of the brain parenchyma, the side effects of such a therapy might overweigh its benefit. As changing R c is difficult, the regulation of Aβ production seems to be the best solution with the least side effects on the system. The production of Aβ is directly related to the expression of synaptic amyloid precursor protein (APP) which gives rise to Aβ if cleaved abnormally [63] . In addition, APP cleavage products alter synaptic plasticity and activity [64, 65] , meaning that Aβ production is not only affected by neural activity, but also affects itself. If such a relation is known, the production of Aβ can be regulated by neural stimulation which brings about broad new therapeutic schemes focusing on electrical stimulation of neurons to regulate Aβ production for AD prevention.
All in all, as Karran et al. reviewed in 2011 [66] , the complexity of the disease has not been understood completely such that many clinical trials focusing on reducing the production of Aβ failed because the disease had already shifted to a new phase, where many other pathological and neuroinflammatory factors entered. In this regard, it is difficult to directly relate the model results to clinical trials. Nevertheless, the model predicts which treatment strategies could be more effective, essentially before the onset of the disease. For instance, we can safely argue that targeting less amyloid production at the first place is equally effective as avoiding ApoE4, but far more beneficial than the clearance through antibodies due to the scaling laws we have obtained from the model. 
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